Valuation: Orgenesis Inc

Market Cap 985K 870K 823K 743K 1.4M 94.4M 1.42M 9.85M 3.79M 48.27M 3.7M 3.62M 155M P/E 2023
-0.26x
P/E 2024 -0.17x
Enterprise Value 19.17M 16.92M 16.01M 14.45M 27.27M 1.84B 27.6M 192M 73.77M 939M 71.96M 70.39M 3.02B EV / Sales 2023
71.2x
EV / Sales 2024 27x
Free-Float
52.06%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 72 01/02/2012
Chief Executive Officer 57 23/12/2013
Director of Finance/CFO 51 09/03/2026
Director TitleAgeSince
Chairman 57 13/08/2014
Director/Board Member 64 07/07/2024
Director/Board Member 47 27/10/2024
Change 5-day change 1-year change 3-year change Capi.($)
+17.76%+8.82% - - 5.68M
-2.10%-4.69%-25.75%+2.04% 175B
-0.92%-4.94%-8.17%+10.12% 111B
-0.90%+0.11%-25.55%+0.78% 107B
+0.69%+0.76%-47.04%-11.84% 75.31B
-2.39%-4.51%-2.54%+66.83% 58.7B
-1.63%-2.19%-2.72%-30.76% 49.57B
+1.53%+4.31%+15.99%+53.87% 49.27B
-2.11%+0.13%-17.19%+19.42% 42.02B
-0.40%-3.62%+29.84%-7.51% 32.69B
Average +0.95%-0.69%-9.24%+11.44% 77.84B
Weighted average by Cap. -1.09%-1.13%-15.60%+8.99%

Financials

2023 2024
Net sales 530K 468K 443K 400K 754K 50.78M 763K 5.3M 2.04M 25.97M 1.99M 1.95M 83.38M 1.03M 914K 864K 780K 1.47M 99.17M 1.49M 10.34M 3.98M 50.71M 3.89M 3.8M 163M
Net income -55.36M -48.86M -46.23M -41.73M -78.78M -5.3B -79.71M -553M -213M -2.71B -208M -203M -8.71B -48.16M -42.51M -40.22M -36.31M -68.54M -4.62B -69.35M -481M -185M -2.36B -181M -177M -7.58B
Net Debt 21.78M 19.23M 18.19M 16.42M 31M 2.09B 31.37M 218M 83.84M 1.07B 81.79M 80.01M 3.43B 18.18M 16.05M 15.18M 13.71M 25.87M 1.74B 26.18M 182M 69.98M 891M 68.26M 66.78M 2.86B
Logo Orgenesis Inc
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Employees
-